ESG NOW intro episode 162
Antibiotic Resistance and What is ESG?
Antibiotic resistance is more worrisome than ever. It is possible that by 2050, three times as many people could die a year as died during the worst parts of the COVID-19 pandemic. But there may be hope in the development of novel antibiotics. We discuss how this is related to the development of the COVID-19 vaccine. Then we finally put ESG ratings in their rightful place and tell you what they are REALLY used for.
Social Sharing
Antibiotic Resistance and What is ESG? - ESG Now: Episode 162
Antibiotic Resistance and What is ESG? (18:37)
十二月 17, 2021
MSCI ESG Now: Episode 162
ep162 -featuring
Subscribe to Our Podcast:
Follow our podcast:
ESG Now Podcast platforms
Related content - episode 162
ESG Now Podcast
ESG explored. A rotating cast of researchers on environmental, social, and governance issues join hosts Mike Disabato and Bentley Kaplan as they discuss the most pressing news of the week. But in an enjoyable way.
Previous EpisodesPutting ESG Ratings in Their Rightful Place
An ESG rating provides only one lens — a financial relevance lens that zooms in on questions of business resilience. That means answering other questions requires using other lenses.
Learn More